-
31.发明授权
公开(公告)号：KR100985254B1
公开(公告)日：2010-10-04
申请号：KR1020070109645
申请日：2007-10-30
Applicant: 한올바이오파마주식회사
CPC classification number: A61K31/00 , A61K9/2077 , A61K9/209
Abstract: 본 발명은 방출성이 제어된 안지오텐신―Ⅱ―수용체 차단제와 HMG-CoA 환원효소 억제제의 복합 조성물에 관한 것으로서, 복합 성분 각각의 체내 약리 작용 발현 시간에 차이를 두어 투약하는 원리를 적용하여 각 성분을 특정 속도로 제어 방출할 수 있도록 설계한 복합 조성물에 관한 발명으로서 당뇨병, 비만증, 고지혈증, 관상 동맥 질환 등이 복합적으로 나타나는 이른바 대사성 증후군을 지닌 자들의 고혈압 치료와 합병증 예방에 매우 효과적인 약학 조성물 및 그의 제제화 방법에 관한 것이다. 보다 상세하게는 특정 속도로 약물을 제어 방출 하도록 설계된 약물 송달 시스템으로서 체내 흡수시 가장 이상적인 효과를 나타낼 수 있도록 하였으며, 환자의 복약 순응도를 높여 외적인 요소에서도 효과를 극대화시킬 수 있는 방출성이 제어된 안지오텐신―Ⅱ―수용체 차단제와 HMG-CoA 환원 효소 억제제의 시간차 투여 복합 조성물에 관한 것이다.
안지오텐신―Ⅱ―수용체 차단제, HMG-CoA 환원 효소 억제제, 고혈압, 고지질혈증, 제어방출제제, 시간차 투약-
公开(公告)号：KR1020090114331A
公开(公告)日：2009-11-03
申请号：KR1020090037420
申请日：2009-04-29
Applicant: 한올바이오파마주식회사
CPC classification number: A61K45/06
Abstract: PURPOSE: A pharmaceutical formulation containing an atorvastatin and valsartan is provided to effectively prevent and treat hypertension and hyperlipidemia and optimize drug delivery time. CONSTITUTION: A pharmaceutical formulation contains 1-160 mg of immediate release compartment containing atorvastatin, its isomer, or it pharmaceutically active ingredient, and 1-800 mg of sustained release compartment containing valsartan as a pharmacologically active ingredient, its isomer or its pharmaceutically acceptable salt. The sustained release compartment further comprises a release control material selected from enteric polymer, water insoluble polymer, hydrophobic compound, hydrophilic polymer and their mixture.
Abstract translation: 目的：提供含有阿托伐他汀和缬沙坦的药物制剂，以有效预防和治疗高血压和高脂血症并优化药物输送时间。 组成：药物制剂含有1-160mg含有阿托伐他汀，其异构体或其药物活性成分的速释隔室，以及含有缬沙坦作为药理学活性成分的1-800mg缓释隔室，其异构体或其药学上可接受的盐 。 缓释室还包含选自肠溶聚合物，水不溶性聚合物，疏水化合物，亲水性聚合物及其混合物的释放控制材料。
-
公开(公告)号：KR1020090114330A
公开(公告)日：2009-11-03
申请号：KR1020090037382
申请日：2009-04-29
Applicant: 한올바이오파마주식회사
CPC classification number: A61K45/06
Abstract: PURPOSE: A pharmaceutical formulation containing atorvastatin as an immediate release compartment and telmisartan as a sustained release compartment is provided to enhance drug effect with reduced side effects. CONSTITUTION: A pharmaceutical formulation comprises a sustained release compartment containing telmisartan, its pharmaceutically acceptable salt, its isomer, and an immediate release compartment containing atorvastatin as a pharmacologically active ingredient, its pharmaceutically acceptable salt, or its isomer. The 75% of atorvastatin is released one hour after release of atorvastatin. The telmisartan is released 1 to 4 hours after releasing atorvastatin.
Abstract translation: 目的：提供含有阿托伐他汀作为立即释放隔室和替米沙坦作为缓释隔室的药物制剂，以增强药物作用，减少副作用。 构成：药物制剂包含含有替米沙坦，其药学上可接受的盐，其异构体和含有阿托伐他汀作为药理学活性成分的立即释放隔室，其药学上可接受的盐或其异构体的缓释隔室。 在阿托伐他汀释放1小时后，阿托伐他汀的75％释放。 释放阿托伐他汀后1〜4小时释放替米沙坦。
-
公开(公告)号：KR1020090107955A
公开(公告)日：2009-10-14
申请号：KR1020090030604
申请日：2009-04-09
Applicant: 한올바이오파마주식회사
IPC: A61K31/435 , A61K31/41 , A61K9/52 , A61P9/12
CPC classification number: A61K31/4178 , A61K9/209 , A61K9/28 , A61K9/48 , A61K31/4427 , A61K47/00 , A61K47/30
Abstract: PURPOSE: A pharmaceutical formulation is provided to prevent metabolism interfering function between drugs and side effects with different release time. CONSTITUTION: A pharmaceutical formulation contains immediate release compartment and extended release compartment. The immediate release compartment contains a pharmacologically active olmesartan medoxomil or its pharmaceutically acceptable salt. The extended release compartment contains a pharmacologically active azelnidipine or its pharmaceutically active salt. 85% or more olmesartan medoxomil is released within one hour after releasing olmesartan medoxomil. The azelnidipine is released one to four hours after releasing the olmesartan medoxomil.
Abstract translation: 目的：提供药物制剂，以防止药物之间的代谢干扰功能和不同释放时间的副作用。 构成：药物制剂含有即时释放隔间和延长释放隔间。 立即释放隔室含有药理学活性的奥美沙坦酯或其药学上可接受的盐。 延长释放隔室含有药理活性的阿魏内苷或其药学活性盐。 释放奥美沙坦酯后1小时内释放出85％以上的奥美沙坦酯。 释放奥美沙坦酯后1至4小时释放阿魏酸。
-
公开(公告)号：KR1020090091080A
公开(公告)日：2009-08-26
申请号：KR1020090014851
申请日：2009-02-23
Applicant: 한올바이오파마주식회사
Abstract: A pharmaceutical formulation for treating cardiovascular diseases, which contains an atorvastatin and amlodipine is provided to prevent antagonism and side effect and easily administer by a patient. A pharmaceutical formulation comprises an immediate compartment having an atorvatatin as a pharmacological active ingredient, its pharmaceutical acceptable salt and an amlodipine as a pharmacological active ingredient or its pharmaceutically acceptable salt. The 90% of atorvastatin is released within one hour after releasing. The amlodipine strats to release after the atorvastatin is released and is released for eight hours. The amlodipine is (S) isomer, (R) isomer, or racemic body.
Abstract translation: 提供用于治疗心血管疾病的药物制剂，其含有阿托伐他汀和氨氯地平以防止拮抗作用和副作用并容易地由患者施用。 药物制剂包含具有作为药理活性成分的阿托伐他汀，其药学上可接受的盐和氨氯地平作为药理活性成分或其药学上可接受的盐的立即隔室。 阿托伐他汀的90％在释放后1小时内释放。 阿托伐他汀释放后放出氨氯地平，释放8小时。 氨氯地平是（S）异构体，（R）异构体或外消旋体。
-
Patent Agency Ranking
公开(公告)号：KR1020090091077A
公开(公告)日：2009-08-26
申请号：KR1020090014652
申请日：2009-02-23
Applicant: 한올바이오파마주식회사
IPC: A61K9/22 , A61K31/44 , A61K31/505 , A61P9/12
Abstract: A pharmaceutical formulation containing a rosuvastatin and amlodipine is provided to improve the adaptation of patient without side effect by administering in the evening. A pharmaceutical formulation comprises an immediate-release compartment having a rosuvastatin as a pharmacologically active ingredient., its isomer, or its pharmaceutically acceptable, an extended-release compartment having an amlodipine pharmacologically active ingredient, its isomer, or its pharmaceutically acceptable salt. The 80% of rosuvastatin is released in 15 minute after releasing. The amlodipine is releases in two hours after releasing. The extended-release compartment is coated with a coating agent of semi-permeable film.
Abstract translation: 提供含有瑞舒伐他汀和氨氯地平的药物制剂，以通过在晚上施用来改善患者的适应性而无副作用。 药物制剂包含具有瑞舒伐他汀作为药理学活性成分的立即释放隔室，其异构体或其药学上可接受的具有氨氯地平药理活性成分，其异构体或其药学上可接受的盐的延长释放隔室。 瑞舒伐他汀的80％在释放后15分钟内释放。 氨氯地平在释放后两小时内释放。 延长释放室涂有半透膜的涂层剂。
-
公开(公告)号：KR1020090017423A
公开(公告)日：2009-02-18
申请号：KR1020080077773
申请日：2008-08-08
Applicant: 한올바이오파마주식회사
CPC classification number: A61K31/35 , A61K31/616 , A61K45/06 , A61K2300/00
Abstract: A combination preparation comprising an inhibitor of HMG-CoA(3-hydroxy-3-methylglutaryl-coenzyme A) reductase and aspirin is provided to remove the side effects due to different medical effects, and reduce the pathogenic risk factor of the cardiovascular disease, thereby reducing the long-term prevention expense. The combination preparation for preventing and treating cardiovascular disease comprises (i) 0.5-80.0 mg of the inhibitor of HMG-CoA reductase which is firstly released from the human body and (ii) 20.0-700.0 mg of aspirin which is secondly released from the human body after 15 minutes to 4 hours after release of the inhibitor of HMG-CoA reductase, wherein the combination preparation is released from the different absorption sites of human body or sequentially released from the same absorption site.
Abstract translation: 提供包含HMG-CoA（3-羟基-3-甲基戊二酰辅酶A）还原酶抑制剂和阿司匹林的组合制剂，以消除由于不同医学效应引起的副作用，并减少心血管疾病的病原性危险因素 减少长期预防费用。 用于预防和治疗心血管疾病的组合制剂包括（i）0.5-80.0mg首先从人体释放的HMG-CoA还原酶抑制剂，和（ii）20.0-700.0mg二次从人体释放的阿司匹林 释放HMG-CoA还原酶抑制剂15分钟至4小时后，其中组合制剂从人体的不同吸收位点释放或从相同吸收部位顺序释放。
-
公开(公告)号：KR100857411B1
公开(公告)日：2008-09-08
申请号：KR1020060068468
申请日：2006-07-21
Applicant: 한올바이오파마주식회사
Abstract: 본 발명은 리파아제 저해제와 1종 이상의 흡착제를 포함하며 리파아제 저해제는 즉시 방출되고 흡착제는 지연 방출되는, 리파아제 저해제의 경구 투여용 약학 제제 및 이의 제조 방법에 관한 것으로, 보다 구체적으로는, 활성 성분으로서 리파아제 저해제를 포함하는 속방출성부 및 약학적으로 허용가능한 흡착제 및 방출조절제를 포함하는 서방출성부을 포함하는 리파아제 저해제의 경구 투여용 약학 제제, 및 1) 서방출성부로서 약학적으로 허용가능한 흡착제를 방출조절제와 혼합하거나 방출조절제로 코팅하여 입자 또는 과립을 제조하는 단계; 2) 속방출성부로서 리파아제 저해제를 통상의 방법으로 입자 또는 과립으로 제조하는 단계; 및 3) 단계 1) 및 2)에서 제조된 입자 또는 과립을 혼합한 후 제제화하는 단계를 포함하는 상기 약학 제제의 제조 방법에 관한 것이다.
본 발명의 약학 제제는 기존의 리파아제 저해제 복용시 발생하는 항문에서의 오일 누출과 같은 부작용을 억제하므로, 비만 및 고지혈증을 예방하고 치료하는데 유용하게 사용될 수 있다.-
公开(公告)号：KR1020080006405A
公开(公告)日：2008-01-16
申请号：KR1020060065586
申请日：2006-07-12
Applicant: 한올바이오파마주식회사
CPC classification number: A61K9/0056 , A61K9/2018 , A61K31/047 , A61K47/36
Abstract: A pharmaceutical composition is provided to simply prepare a tablet having the mechanical strength of 4-5 kp, which has no difficulty in common handling and distribution and is rapidly disintegrated orally to promote the absorption of an active ingredient in vivo, using a conventional general solid formulation manufacturing equipment. A quick-dissolved pharmaceutical composition comprises 1-30 wt.% of loratadine or desloratadine having the pharmaceutically effective anti-histamine activity as an active ingredient, 20-50 wt.% of a water soluble hydrocarbon as an excipient, 30-70 wt.% of a mixture of spray-dried starch and spray-dried lactose as a disintegrating agent, 1-5 wt.% of a disintegrating supplement and 5-20 wt.% of a pharmaceutically acceptable additive such as a sweetening agent, a lubricant, an acid and alkalinizing agent, a foaming agent, and a fine pore forming agent.
Abstract translation: 提供药物组合物以简单地制备机械强度为4-5kp的片剂，这在常规的处理和分配中并不困难，并且使用常规的一般固体口服快速崩解以促进活性成分在体内的吸收 配方制造设备。 快速溶解的药物组合物包含1-30重量％的具有药学有效的抗组胺活性的氯雷他定或去氯雷他定作为活性成分，20-50重量％的作为赋形剂的水溶性烃，30-70重量％ ％的喷雾干燥淀粉和喷雾干燥的乳糖的混合物作为崩解剂，1-5重量％的崩解补充剂和5-20重量％的药学上可接受的添加剂如甜味剂，润滑剂， 酸和碱化剂，发泡剂和细孔形成剂。
-
公开(公告)号：KR1020160141044A
公开(公告)日：2016-12-08
申请号：KR1020150073883
申请日：2015-05-27
Applicant: 한올바이오파마주식회사
IPC: A61K9/00 , A61K47/24 , A61K47/30 , A61K47/40 , A61K31/519
Abstract: 본발명은실데나필, 그약학적으로허용가능한염, 또는그 용매화물인활성성분, 및서방성기제를포함하는실데나필제어방출성경구제제와실데나필제어방출성경구제제제조방법을제공한다. 본발명에의해실데나필, 그약학적으로허용가능한염 또는그 용매화물의복용횟수를줄일수 있어복용편의성을향상시킬수 있으며, 그에따라복약순응성을향상시킬수 있는장점이있다. 또한, 본발명에의해실데나필제어방출성경구제제를효과적으로제조할수 있다는장점이있다.
-
-
-
-
-
-
-
-
-
Search Results
108
records
(took 0.035 seconds)
